Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Key Stats

• Today's Range: $0.22 to $0.25
• 50-Day Range: $0.23 to $84.96
• 52-Week Range: $0.22 to $39.84
• Volume: 2.59 million shs
• Average Volume: 453,490 shs
• Market Capitalization: $5.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

CYCC Stock Analysis - Frequently Asked Questions

How have CYCC shares performed this year?

Cyclacel Pharmaceuticals' stock was trading at $90.24 at the beginning of the year. Since then, CYCC stock has decreased by 99.7% and is now trading at $0.2330.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, April, 2nd. The biotechnology company reported ($79.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($69.60) by $9.60. The biotechnology company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals shares reverse split on the morning of Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 4/02/2025
• Record date for 5/1 Dividend: 4/29/2025
• Ex-Dividend for 5/1 Dividend: 4/29/2025
• Dividend Payable: 5/01/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCC
• CIK: 1130166
• Web: www.cyclacel.com
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($56.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.21 million
• Net Margins: N/A
• Pretax Margin: -55,535.71%
• Return on Equity: -3,648.09%
• Return on Assets: -155.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.60
• Quick Ratio: 5.60

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 138.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.93) per share
• Price / Book: -0.06

Miscellaneous

• Outstanding Shares: 23,760,000
• Free Float: 737,000
• Market Cap: $5.54 million
• Optionable: Optionable
• Beta: 0.03